The Incidence of Myocardial Injury after Loading Doses of Clopidogrel versus Prasugrel in the Candidates for Percutaneous Coronary Intervention: A Randomized Controlled Trial

Critical Pathways in Cardiology
Reza RahmaniAmir Farhang Zand Parsa

Abstract

Prevention of myocardial injury is an essential issue in percutaneous coronary intervention (PCI). We compared the incidence of myocardial injury after loading doses of clopidogrel versus prasugrel in the candidates for PCI. In this randomized-controlled clinical trial, we enrolled 88 stable angina patients, candidate for PCI. Patients received either prasugrel (60 mg orally) (n = 42) or clopidogrel (600 mg orally) (n = 46). Serum levels of creatine phosphokinase muscle-brain type, cardiac troponin I, and high sensitive C-reactive protein were measured at baseline and 6 and 12 hours postprocedural. Primary endpoint was periprocedural myocardial infarction (MI), defined as elevation of cTn values (>5 times) in patients with normal baseline values or a rise of cTn values >20% if the baseline values are elevated. Based on the levels of cTnI 6 hours after PCI, 1 patient (2.4%) had MI in the prasugrel group, whereas 4 patients (8.7%) had MI in the clopidogrel group. After 12 hours, 4 patients (9.5%) had MI in the prasugrel group versus 5 patients (10.9%) in the clopidogrel arm. There was no significant difference between the groups regarding the changes in cardiac specific enzyme levels. However, serum levels of cTnI were significan...Continue Reading

References

Aug 25, 2001·Lancet·S R MehtaUNKNOWN Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
Mar 17, 2005·European Heart Journal·Sigmund SilberUNKNOWN Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Apr 4, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nagy A FaridMark J Goldberg
Nov 22, 2007·Journal of Cardiovascular Pharmacology·Christopher D PayneKenneth J Winters
Jul 31, 2008·American Heart Journal·Dominick J Angiolillo, Piera Capranzano
Jul 31, 2008·American Heart Journal·Dominick J AngiolilloTheodore A Bass
May 14, 2009·European Heart Journal·Alan D MichelsonUNKNOWN TRITON-TIMI 38 Investigators
Sep 11, 2012·Journal of the American College of Cardiology·Kristian ThygesenDaniel R Wagner
Nov 24, 2012·Current Clinical Pharmacology·Hugo Á Del Castillo-CarnevaliJosé L Z Gómez
Feb 23, 2013·Current Opinion in Pharmacology·David J Kurz, Franz R Eberli
Dec 20, 2014·Journal of the American College of Cardiology·Gilles MontalescotUNKNOWN ACCOAST Investigators

❮ Previous
Next ❯

Citations

Jun 27, 2020·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Mohamad SoudHector M Garcia-Garcia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.